human col1a2  (Elabscience Biotechnology)

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Spatial transcriptomics reveals prognostically LYZ + fibroblasts and colocalization with FN1 + macrophages in diffuse large B-cell lymphoma

doi: 10.1007/s00262-025-03968-7

Figure Lengend Snippet: Prognostic significance of autoantibodies against COL1A2, COL3A1, and FN1 in patients with DLBCL receiving R-CHOP ( n = 20 and 125) and NSCLC treated with ICIs ( n = 36). A Volcano plot, boxplot, and representative density plots of patients illustrating the distribution of COL1A2 autoantibodies in DLBCL. B Kaplan–Meier curve for PFS based on COL1A2 autoantibody levels in DLBCL. C Kaplan–Meier curves for OS and PFS in NSCLC patients receiving immunotherapy, stratified by COL1A2 and COL3A1 mRNA levels in GSE128989 and autoantibody presence, alongside representative density plots of COL1A2 and COL3A1 autoantibodies. D Comparison of FN1 autoantibody levels between healthy controls and DLBCL, with Kaplan–Meier analysis for PFS based on FN1 autoantibody levels. DLBCL: diffuse large B cell lymphoma; R-CHOP: rituximab, cyclophosphamide, doxorubicin: vincristine, and prednisone; NSCLC: non-small cell lung cancer; ICIs: immune checkpoint inhibitor; OS: overall survival; and PFS: progression-free survival

Article Snippet: Rabbit anti-human COL1A2 IgG antibody , sc-393573 , Santa Cruz Biotechnology.

Techniques: Comparison

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Spatial transcriptomics reveals prognostically LYZ + fibroblasts and colocalization with FN1 + macrophages in diffuse large B-cell lymphoma

doi: 10.1007/s00262-025-03968-7

Figure Lengend Snippet: Reagents and tools table

Article Snippet: Rabbit anti-human COL1A2 IgG antibody , sc-393573 , Santa Cruz Biotechnology.

Techniques: Formalin-fixed Paraffin-Embedded, Gene Expression, RNA Sequencing, Sequencing, Biomarker Discovery, Clinical Proteomics, Microarray, Control, Immunohistochemistry, Microscopy, Immunofluorescence, Software

Journal: Chemical Engineering Journal

Article Title: Revolutionizing wound healing: Ultrashort pulse electric fields in seconds for highly aligned extracellular matrix and efficient cell migration

doi: 10.1016/j.cej.2023.144267

Figure Lengend Snippet: Fig. 1. Enhanced cell migration and growth factor secretion under μsPEF. (a) A graphical illustration showed the effects of μsPEF (pulse width:20 μs, frequency: 10 Hz, duration: 5 s) on the skin wound, promoting cell migration and extracellular matrix remodeling. (b) Box plot showing the average cell migration speed with different intensity μsPEF (i.e., from 250 V/cm to 1500 V/cm) and control group in 12 h. Results are presented as mean ± standard error of mean with 95% CI. *p < 0.05, ****p < 0.0001 versus control by one-way ANOVA for multiple comparisons. (c) Representative time-lapse images showing the fibroblasts morphology after μsPEF (i.e., 750 and 1500 V/cm) treatment of different intensity at different time points (i.e., 0, 1 and 2 h). Detached cells are marked by yellow arrow. Scale bar, 50 μm. (d) The line graph representing the cell migration average speed per 1 h from 0 to 12 h after different intensity μsPEF (i.e., 750 and 1500 V/cm) treatment (blue circle: control; orange square: 750 V/cm; pink triangle: 1500 V/cm). Results are presented as mean ± standard deviation with 95% CI (nCTRL = 42 cells, n750 v/cm = 48 cells, n1500 v/cm = 47 cells); *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 versus control by one-way ANOVA for multiple comparisons. (e) Box plot showing the average cell migration speed with different intensity μsPEF (i.e., 750 and 1500 V/cm) and control treatments in 24 h. Results are presented as mean ± standard error of mean with 95% CI (nCTRL = 470 cells, n750 V/cm = 979 cells, n1500 V/cm = 535 cells). (f) Effects of μsPEF on the secretion of COLA2. The level of collagen type I α2 in cellular supernatants was measured after 48 h. The concentration of COLA2 was 0.109 ± 0.018 ng/mL in the control group, 0.257 ± 0.058 ng/mL in the 750 V/ cm group and 0.363 ± 0.034 ng/mL in the 1500 V/cm group. Results are presented as mean ± standard deviation with 95% CI (n = 5); *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 versus control by one-way ANOVA for multiple comparisons. (g) Effects of μsPEF on the expression of FGF2. The level of FGF2 in cellular supernatants was measured after 48 h. The concentration of FGF2 was 44.139 ± 0.360 ng/mL in the control group, 48.012 ± 1.488 ng/mL in the 750 V/cm group and 48.523 ± 1.944 ng/mL in the 1500 V/cm group. Results are presented as mean ± standard deviation with 95% CI (n = 3); ns = 0.7329, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 versus control by one-way ANOVA for multiple comparisons. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

Article Snippet: Then, the cells were cultured in serum-free medium for 48 h. The content of type I α collagen and basic fibroblast growth factor (FGF-2) in the supernatant were measured using commercially available Human COL1A2 (Collagen Type I Alpha 2) ELISA Kit (Elabscience, Wuhan, China) and Human bFGF/FGF2 (Basic Fibroblast Growth Factor) ELISA Kit (Elabscience, Wuhan, China) according to the manufacturer’s protocol respectively.

Techniques: Migration, Control, Standard Deviation, Concentration Assay, Expressing

Journal: Cells

Article Title: Ultrastructural Characterization of Human Gingival Fibroblasts in 3D Culture.

doi: 10.3390/cells11223647

Figure Lengend Snippet: Figure 2. Immunofluorescence analysis. (A) Characterization by of a population of hGFs. Positive markers panel: Vim, Col1A2, PDGFRβ, Itgβ1, and αSMA. Cells were negative for STIM1 and Stro-1. (B) hGFs spheroids express STIM1. Scale bar, 200 µm; 10× magnification. The data are from three representative experiments.

Article Snippet: The populations of hGFs cultured in the monolayer and in spheroids were characterized by immunofluorescence staining using the following primary antibodies: anti-human vimentin (Vim) (1:1000) (Abcam, Cambridge, UK), anti-human collagen type I alpha 2 chain (Col1A2) (Proteintech, Rosemont, IL, USA) (1:1000), anti- human α-smooth muscle actin (αSMA) (1:50) (Proteintech, Rosemont, IL, USA), anti-human integrin βeta1 (Itgβ1) (1:50) (Proteintech, Rosemont, IL, USA), anti-human platelet-derived growth factor receptor beta (PDGFRβ) (1:20) (GeneTex, Irvine, CA, USA), anti-human stromal interacting molecule 1 (STIM1) (1:50) (Abcam, Cambridge, UK), and anti-human Stro-1 (Stro-1) (Abcam, Cambridge, UK).

Techniques: